drugset / Trial / NCT03402789

Docosahexaenoic Acid (DHA) Supplementation in Amblyopia

NCT03402789 ↗

Phase 1/2 Withdrawn Johns Hopkins University
RandomizedParallel-groupSingle-blindTreatment

Summary

This study evaluates the addition of docosahexaenoic acid (DHA) to eye patching in the treatment of residual amblyopia in children ages 3 to 18 years old. Two thirds of participants will receive DHA along with eye patching, while one third of participants will receive a placebo along with eye patching.

Timeline

Start
2024-01-01
Primary completion
2024-07-01
Completion
2024-12-30

Outcome

Outcome not reported

Stopped (Business): “Hopkins failed to review contract with company providing complimentary dha, support was withdrawn necessitating me to get more grant money to fund study which was unsucccessful.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject DOCONEXENT Other / unclassified 1200 mg Oral

Indications